A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has discovered a new mechanism showing how butyrate – a short-chain fatty acid produced by gut bacteria – enhances T helper (Tfh) activity to promote antibody production and enhance mucosal immunity.
This study identifies a novel microbe-immune-antibody production axis that links microbial metabolism to mucosal immune responses, providing a strategy to maximize the protective effects of mucosal vaccines. The findings were recently published in the international journal Microbiome.
Mucosal vaccines and the challenge they face
Mucosal vaccines are gaining attention as a next-generation vaccination approach because they can be delivered noninvasively and elicit immune responses directly at mucosal surfaces such as the gut or common sites of respiratory tract infection.
However, their development has been hindered by several challenges: antigens must survive harsh gastric conditions, cross mucus barriers and overcome the permissive gut environment. Consequently, these vaccines often require high doses of antigen, strong adjuvants, or complex delivery systems, raising safety and cost concerns. The present study provides a novel solution by demonstrating that butyrate, a naturally occurring microbial metabolite, acts as an innate adjuvant that enhances mucosal vaccine responses safely and effectively.
Key findings: A microbiota–Tfh–IgA axis
Although the gut microbiota is known to play a critical role in maintaining immune homeostasis, its influence on mucosal antibody responses remains unclear.
The POSTECH-ImmunoBiome team discovered that Peyer’s patch-derived Tfh cells in the small intestine have a much stronger ability to induce IgA antibody production than spleen Tfh cells. When antibiotic treatment (neomycin) depleted specific bacterial groups, both faecal IgA levels and Tfh cell frequencies were significantly reduced. these effects were restored after faecal microbial transplantation. Further analysis identified Lachnospiraceae and Ruminococcaceae, the main butyrate-producing taxa, as key microbial agents supporting the Tfh-IgA axis.
Mechanistic studies revealed that butyrate promotes Tfh differentiation and the formation of IgA+ germinal center B cells, thereby enhancing mucosal IgA production. Administration of tributyrin, a butyrate prodrug, significantly increased IgA responses and protection against Salmonella Typhimurium infection, reducing both infection rates and tissue damage. This effect was abrogated in GPR43-deficient cells, confirming that the butyrate-GPR43 signaling pathway mediates Tfh activation and IgA induction.
Consequences
This study demonstrates that butyrate, a metabolite produced by gut microbes, establishes a novel microbiota-Tfh-IgA axis, linking integrin metabolism to antibody-mediated mucosal defense. These results highlight the critical role of regulating the gut environment in controlling infections and enhancing vaccine responses.
Our findings reveal that gut microbes are not just passive residents, but active regulators of the immune system. Microbial metabolites can directly enhance the function of immune system cells that are essential for antibody production and vaccine effectiveness. This discovery opens new avenues for the development of microbiota-based adjuvants and next-generation mucosal vaccines.”
Prof. Sin-Hyeog Im, POSTECH and CEO of ImmunoBiome, Inc.
Source:
Journal Reference:
